The stress hormone COrtisol and the development of MEtabolic Syndrome and Cardiovascular DIseases Unravelling the cause(s) of hypercortisolism in obesity: Investigating the influence of the liver, gut and immune system

The stress hormone COrtisol and the development of MEtabolic Syndrome and Cardiovascular DIseases Unravelling the cause(s) of hypercortisolism in obesity: Investigating the influence of the liver, gut and immune system - COMEDI

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54740

Enrollment

200

Registered

2019-06-06

Start date

2020-01-30

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome Obesity

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Eligibility for bariatric surgery according to the current clinical standards sufficient scalp hair for analysis

Exclusion criteria

Exclusion criteria: medication that interferes with the cortisol, the microbiome or the immune system abnormal renal function diseases or conditions leading to hepatic steatosis ( e.g. alcohol, viral hepatitis, hepatotoxic drugs)

Design outcomes

Primary

Measure	Time frame
The relation between hepatic steatosis, cortisol status, immune status and gut microbiota in patients with obesity, in association with weight changes (because of bariatric surgery or a CLI)	—

Secondary

Measure	Time frame
Secondary Objective(s): - To study the differential weight-reducing treatments (1. Bariatric surgery and 2. Combined lifestyle intervention) on cortisol status, immunological factors, and gut microbioma	—

Countries

Netherlands

Outcome results